RxDoctor Payments Data

Juliet Thornton

Family · Fayette, ALNPI 1447864160

Payments from drug & device makers

$601in general payments, 2019–2025

Across 34 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$170
  • AbbVie$91
  • AstraZeneca$70
  • GSK$64
  • Lilly USA, LLC$49
  • Amgen$34
  • plus $124 from 6 others

What the payments were for

  • Food & beverage$601100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$601 in reported general payments places this provider in the 55th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$17,063
Medicare patients
118
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$48,581
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$37,885
TrulicityDulaglutide20$34,355
JardianceEmpagliflozin28$26,969
EliquisApixaban38$26,607
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$20,995
JanuviaSitagliptin Phosphate23$18,049
FarxigaDapagliflozin Propanediol19$14,292
MounjaroTirzepatide11$11,383
LinzessLinaclotide13$11,327
XareltoRivaroxaban14$9,300
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,354
VascepaIcosapent Ethyl13$4,073
Potassium Chloride63$2,891
Carvedilol ErCarvedilol Phosphate12$2,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$170$48,58150 claims
Lilly USA, LLCTrulicity, Mounjaro$49$45,73731 claims
GSKTrelegy Ellipta$64$37,88536 claims
Boehringer IngelheimJardiance$28$26,96928 claims
AstraZenecaFarxiga$70$14,29219 claims
AbbVieLinzess$91$11,32713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,415 family providers in Alabama.

Other family in Fayette

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →